The T800 (CR4/CR5 full domain) and T1000 (P6.1 fork) were selected as therapeutic aptamers while the same sequence, but with the mutation present in DC patients (G305A for T1000 aptamer) was selected as control. This evidence concerns the gene CRIPTOP4 and dyskeratosis congenita.